Holistick Medical

medical devices

About

Holistick Medical is an early-stage MedTech company founded in 2017 by Truffle Capital. The company focuses on developing a minimally invasive catheter-based device to treat common cardiac defects, particularly Patent Foramen Ovale (PFO). This septal defect can contribute to strokes in young individuals. Holistick's innovative device is designed to repair heart holes and other tissue defects without sutures or rigid implants, using flexible, deployable soft patches that promote tissue regeneration. The device aims to provide a small-footprint closure of PFO, which affects about 25% of the population. It encourages the reconstitution of normal tissue, eliminating the need for permanent bulky implants and facilitating access to difficult-to-reach organs. Holistick Medical targets cardiologists and healthcare providers specializing in cardiac interventions, particularly those treating patients at risk of PFO-related strokes. The company has secured significant funding, including an initial €85 million from Truffle Capital’s BioMedTech fund, to support the development and commercialization of its technology.

Technologies

Outlook Amazon AWS Google Plus Google Font API Mobile Friendly AI

Keywords

medical equipment manufacturing cardiac defect treatment healthcare equipment & supplies biocompatible patch minimally invasive device cardiology medical devices biomedical engineering medical equipment and supplies manufacturing device development pfo closure future therapy options heart defect repair medical technology biomedical innovation preclinical development b2b regulatory compliance disruptive heart defect device light-activated patch biotechnology patient care product development nonmetallic device venture capital cardiology innovation cardiac physiology preservation medical device clinical readiness atrial septal defect

Location

53 Rue de Turbigo, Paris, Ile-de-France, France, 75003

Related Companies

Companies in the same industry